secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q/C TECHNOLOGIES, INC. (QCLS)
CIK:        0001321834
Form:       8-K
Filed at:   2023-03-20T23:59:59+00:00
Accession:  0001493152-23-008200
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MyMD Pharmaceuticals announces positive preclinical data for MYMD-1 in RA model
-------------------------------------------------------------------------------

- MYMD-1 reduced histopathological changes vs placebo (p<0.0001 composite score) in RA model.
- Disease severity reduced 47% with MYMD-1 450 mg/kg/day orally vs 37% for etanercept.
- Oral TNF-α inhibitor shows potential to disrupt current market; early-stage RA trials planned.
- Data presented at 2023 Society of Toxicology Annual Meeting on March 20, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223008200/0001493152-23-008200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223008200/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-008200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer